Arvinas, Inc. (NASDAQ: ARVN) to report earnings of $ -0.78 per share
Analysts expect Arvinas, Inc. (NASDAQ: ARVN) to report ($ 0.78) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Eight analysts have released earnings estimates for Arvinas, with the highest estimate of EPS at ($ 0.37) and the lowest estimate at ($ 1.30). Arvinas posted earnings of ($ 0.99) per share for the same quarter last year, which would suggest a positive year-over-year growth rate of 21.2%. The company is expected to release its next quarterly results on Monday, March 7.
On average, analysts expect Arvinas to report annual earnings of ($ 3.60) per share for the current year, with EPS estimates ranging from $ 4.10 to ($ 3.17). For the next fiscal year, analysts expect the company to report earnings of ($ 3.23) per share, with EPS estimates ranging from ($ 4.60) to ($ 1.84). Zacks’ earnings per share calculations are an average based on a survey of research companies that cover Arvinas.
Arvinas (NASDAQ: ARVN) last announced its results on Wednesday, November 3. The company reported ($ 0.94) EPS for the quarter, missing the Thomson Reuters consensus estimate of $ 2.13 per ($ 3.07). Arvinas had a negative net margin of 794.97% and a negative return on equity of 27.02%. The company posted revenue of $ 9.28 million in the quarter, compared to $ 26.89 million expected by analysts. In the same quarter of the previous year, the company achieved EPS ($ 0.79). The company’s revenue for the quarter increased 22.2% year-over-year.
ARVN has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Arvinas shares from a “buy” rating to a “hold” rating in a report released on Tuesday, October 12. Oppenheimer upgraded Arvinas shares from a “market performance” rating to an “outperformance” rating in a report released Thursday, November 4. Stifel Nicolaus launched coverage on Arvinas shares in a report on Wednesday, September 29. They set a “buy” rating and a price target of $ 115.00 for the company. SVB Leerink began covering Arvinas shares in a report on Thursday, October 14. They set an “outperformance” rating and a price target of $ 115.00 for the company. Finally, Bank of America began covering Arvinas shares in a research note on Thursday, September 9. They issued a “buy” note and a target price of $ 110.00 for the company. One investment analyst rated the stock with a conservation rating and fifteen gave the company’s stock a buy rating. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $ 128.71.
The NASDAQ ARVN opened at $ 73.40 on Friday. Arvinas has a 52 week low of $ 56.59 and a 52 week high of $ 108.46. The company has a 50-day simple moving average of $ 81.40 and a 200-day simple moving average of $ 83.94. The company has a market cap of $ 3.88 billion, a PE ratio of -19.32 and a beta of 1.95.
In other Arvinas news, director Liam Ratcliffe sold 85,705 Arvinas shares in a trade that took place on Thursday, December 16. The shares were sold at an average price of $ 69.36, for a total trade of $ 5,944,498.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Additionally, insider Ian Taylor sold 20,000 Arvinas shares in a trade that took place on Monday, November 15. The shares were sold at an average price of $ 84.04, for a total trade of $ 1,680,800.00. Disclosure of this sale can be found here. Insiders sold 482,657 shares of the company valued at $ 37,757,660 in the past 90 days. 6.45% of the shares are held by insiders of the company.
A number of institutional investors have recently changed their positions in ARVN. Royal Bank of Canada purchased a new stake in Arvinas during the first quarter valued at approximately $ 143,000. Alliancebernstein LP increased its position in Arvinas by 16.1% in the second quarter. Alliancebernstein LP now owns 54,800 shares of the company valued at $ 4,220,000 after purchasing an additional 7,600 shares in the last quarter. The New York State Common Retirement Fund increased its position in Arvinas by 20.8% in the second quarter. The New York State Pooled Retirement Fund now owns 37,682 shares of the company valued at $ 2,902,000 after purchasing an additional 6,482 shares in the last quarter. Arizona State Retirement System increased its position in Arvinas by 7.7% during the second quarter. Arizona State Retirement System now owns 9,696 shares of the company valued at $ 747,000 after purchasing an additional 697 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in Arvinas by 70.5% during the second quarter. Victory Capital Management Inc. now owns 10,559 shares of the company valued at $ 813,000 after purchasing an additional 4,367 shares in the last quarter. Institutional investors and hedge funds hold 99.83% of the company’s shares.
Arvinas Company Profile
Arvinas, Inc is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies to break down disease causing proteins. Its product candidates are ARV-110, a chimeric protein degrader targeting proteolysis (PROTAC) which is in a Phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with cancer of. metastatic castration-resistant prostate; and ARV-471, a PROTAC protein degrader targeting estrogen receptor protein for the treatment of patients with ER positive / HER2 negative metastatic breast cancer.
Featured article: Why are bearish stocks important?
Get a free copy of Zacks’ research report on Arvinas (ARVN)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Arvinas now?
Before you consider Arvinas, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the wider market takes hold … and Arvinas was not on the list.
While Arvinas currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here